Moxibustion for essential hypertension

Elevated blood pressure, known as essential hypertension, represents one of the major public health challenges in the contemporary world. This condition affects millions of people globally and is directly related to serious cardiovascular complications, including strokes and heart attacks. Studies demonstrate that approximately 62% of strokes and 49% of myocardial infarctions are caused by high blood pressure, making it the leading risk factor for mortality worldwide. Despite advances in treatment with conventional antihypertensive medications, many patients still face significant limitations, whether due to lack of access to medications, high costs, or undesired adverse effects.

This reality has led approximately 30% of hypertensive individuals to remain undiagnosed, while more than 40% do not receive adequate treatment. Given this scenario, many patients have sought alternatives in complementary medicine, including traditional Chinese medicine practices such as moxibustion.

Moxibustion is a millennia-old therapeutic technique that consists of applying heat through the controlled burning of mugwort (Artemisia vulgaris) over specific body points, similar to those used in acupuncture. This practice has aroused growing interest as a complementary treatment for hypertension, based on the Chinese medicine theory that heat can improve the circulation of vital energy and regulate the functions of internal organs. The objective of this study was to systematically evaluate the available scientific evidence on the efficacy of moxibustion in the treatment of essential hypertension.

The researchers conducted a rigorous systematic review, following international standards established by the Cochrane Collaboration. Seven electronic databases were searched, including both Western and Chinese databases, through March 2013, looking for randomized clinical trials testing moxibustion alone or combined with antihypertensive medications, comparing it with conventional drug treatment. The search was particularly comprehensive in Chinese databases, where most research on moxibustion is conducted. After careful analysis, five randomized clinical trials meeting the inclusion criteria were selected, involving a total of 357 patients with essential hypertension.

All included studies were published in Chinese and used internationally recognized diagnostic criteria for hypertension. Treatments varied in duration from 10 to 30 days, and all studies used blood pressure as the primary efficacy measure.

The results revealed distinct findings depending on how moxibustion was applied. When used alone compared with antihypertensive medications, moxibustion did not demonstrate statistically significant superiority in blood pressure control. However, when combined with conventional medications, the results were more promising. Statistical analysis showed that patients who received moxibustion together with antihypertensive medications presented significant reductions in both systolic and diastolic pressure compared with those who received only medications.

Specifically, there was a mean reduction of approximately 9.57 mmHg in systolic pressure and 4.08 mmHg in diastolic pressure, differences considered clinically relevant. In addition, the overall efficacy rate of combined treatment was 3.35 times higher than treatment with medications alone.

For patients and healthcare professionals, these results suggest that moxibustion may have a role as complementary therapy in the management of hypertension, particularly when used in conjunction with conventional drug treatment. This integrative approach may especially benefit patients who present inadequate blood pressure control with medications alone, or those who seek to reduce medication dosage due to side effects. It is important to emphasize that the results do not support the use of moxibustion as a complete substitute for antihypertensive medications, but rather as a potentially useful complement. For healthcare professionals, this evidence may inform discussions about integrated therapeutic options, always considering individual patient preferences and needs.

The observed reduction in blood pressure, although modest, may significantly contribute to long-term cardiovascular risk reduction.

However, the authors highlight important limitations that must be considered in the interpretation of these results. The methodological quality of the included studies was considered generally low, with significant deficiencies in the design and conduct of the research. Most studies did not provide adequate details on randomization methods, did not use adequate blinding techniques, and presented small sample sizes without appropriate statistical calculations to determine study power. Additionally, the safety question remains poorly clarified, as only one of the five studies reported information on adverse effects, finding no significant problems, but the remaining studies simply did not address this important issue.

The absence of robust safety data is particularly concerning given the growing worldwide interest in complementary therapies.

In conclusion, although the results suggest potential benefits of moxibustion as complementary therapy for hypertension, the limited quality of the available evidence prevents definitive conclusions about its efficacy and safety. The authors emphasize the urgent need for more rigorous clinical studies, with better methodological quality, larger samples, and adequate safety evaluation to conclusively establish the role of moxibustion in the treatment of hypertension. Patients interested in this approach should discuss it with their physicians, always maintaining conventional drug treatment and considering moxibustion only as a possible complementary therapy. Future research should focus on overcoming the identified limitations to provide more robust evidence that can adequately guide evidence-based clinical practice.